Holen Sie sich die Stockscreener-App
99.60
1.13%
1.11
Handel nachbörslich:
99.78
0.18
+0.18%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$98.49
Offen:
$98.41
24-Stunden-Volumen:
6.96M
Relative Volume:
0.76
Marktkapitalisierung:
$172.35B
Einnahmen:
$46.59B
Nettoeinkommen (Verlust:
$5.41B
KGV:
32.19
EPS:
3.0938
Netto-Cashflow:
$7.38B
1W Leistung:
+2.15%
1M Leistung:
-5.35%
6M Leistung:
-3.04%
1J Leistung:
-25.29%
1-Tages-Spanne:
$98.20
$100.36
1-Wochen-Bereich:
$97.20
$100.95
52-Wochen-Spanne:
$81.97
$135.12
Abbott Laboratories Stock (ABT) Company Profile
Firmenname
Abbott Laboratories
Sektor
Branche
Telefon
(224) 667-6100
Adresse
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs MDT, SYK, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
99.60 | 172.35B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
88.48 | 113.18B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
277.33 | 106.38B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
42.73 | 61.93B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
85.21 | 49.12B | 6.30B | 1.07B | 1.09B | 1.8406 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-10-07 | Eingeleitet | Barclays | Overweight |
| 2026-10-02 | Hochstufung | Rothschild & Co Redburn | Neutral → Buy |
| 2026-08-13 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2026-07-01 | Eingeleitet | Robert W. Baird | Outperform |
| 2026-04-22 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2025-10-10 | Eingeleitet | The Benchmark Company | Buy |
| 2025-07-18 | Hochstufung | Jefferies | Hold → Buy |
| 2025-06-16 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-10-08 | Eingeleitet | Oppenheimer | Outperform |
| 2024-09-19 | Eingeleitet | Piper Sandler | Overweight |
| 2024-07-30 | Herabstufung | Edward Jones | Buy → Hold |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2023-07-21 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | Bestätigt | Barclays | Overweight |
| 2023-04-20 | Bestätigt | Bernstein | Outperform |
| 2023-04-20 | Bestätigt | JP Morgan | Overweight |
| 2023-04-20 | Bestätigt | Raymond James | Outperform |
| 2023-04-20 | Bestätigt | UBS | Buy |
| 2023-04-20 | Bestätigt | Wolfe Research | Underperform |
| 2023-03-29 | Eingeleitet | UBS | Buy |
| 2022-10-26 | Eingeleitet | Mizuho | Neutral |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-07-06 | Eingeleitet | Wolfe Research | Underperform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-01-27 | Bestätigt | Credit Suisse | Outperform |
| 2022-01-27 | Bestätigt | Morgan Stanley | Overweight |
| 2022-01-27 | Bestätigt | Raymond James | Outperform |
| 2022-01-27 | Bestätigt | UBS | Buy |
| 2021-12-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-10-27 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | Eingeleitet | Redburn | Neutral |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Neutral |
| 2021-01-28 | Hochstufung | BTIG Research | Neutral → Buy |
| 2020-09-11 | Eingeleitet | Wolfe Research | Outperform |
| 2020-06-01 | Herabstufung | Goldman | Neutral → Sell |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2020-02-13 | Eingeleitet | Goldman | Neutral |
| 2020-02-06 | Fortgesetzt | BTIG Research | Neutral |
| 2020-01-02 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-06-13 | Bestätigt | BofA/Merrill | Buy |
| 2019-02-07 | Bestätigt | BofA/Merrill | Buy |
| 2019-01-02 | Herabstufung | Citigroup | Neutral → Sell |
| 2018-11-30 | Hochstufung | Goldman | Neutral → Buy |
| 2018-10-16 | Eingeleitet | Barclays | Overweight |
| 2018-06-27 | Eingeleitet | Bernstein | Outperform |
| 2018-01-30 | Bestätigt | Citigroup | Neutral |
| 2018-01-25 | Bestätigt | Stifel | Buy |
| 2018-01-25 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | Eingeleitet | Evercore ISI | Outperform |
| 2018-01-02 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-01-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-10-19 | Bestätigt | Stifel | Buy |
Alle ansehen
Abbott Laboratories Aktie (ABT) Neueste Nachrichten
A Stock Market Crash Is Coming By the End of 2027, According to Some Economists. Here Are 2 Stocks to Buy Before That Happens - The Motley Fool
Is it the Right Time to Hold TNDM Stock in Your Portfolio? - Zacks Investment Research
China Adult Feeding Tubes and Formula Market Outlook to 2033Revenue, Volume, Pricing, and Company Share | Forecast Data Reveals Market Entry and Expansion Opportunities - GlobeNewswire Inc.
Is it the Right Time to Add Phibro Stock to Your Portfolio? - Zacks Investment Research
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know - Zacks Investment Research
Abbott Laboratories Contamination Lawsuit Ends in $385 Million Settlement — But Nobody's Admitting Anything - https://www.lawnews.co.uk/
Abbott (ABT) Stock Drops Despite Market Gains: Important Facts to Note - Zacks Investment Research
What Will the Libre Duo Launch Mean for Abbott Laboratories (NYSE:ABT)? - Kalkine Media
Abbott Laboratories stock: FDA approves new CardioMEMS capabilities - AD HOC NEWS
Did Heart Failure Device Updates Just Shift Abbott Stock’s Investment Narrative? - Simply Wall Street
Global Bioelectronic Medicine Market Anticipates Impressive Growth Trajectory of ~10% by 2034 | DelveInsight - GlobeNewswire Inc.
Better Dividend Play for Retirees: MDT or ABT? One Delivers Significantly More Yield - 24/7 Wall St.
Abbott Laboratories stock trades 26.5 percent below its yearly high - AD HOC NEWS
Can J&J's MedTech Business Rebound in Q3 After Q2 Slowdown? - Zacks Investment Research
Redburn upgrades Abbott Laboratories stock to Buy - AD HOC NEWS
Global Microfluidics Market by Product Type, Application, End User, and Region, 2026-2036 | $48.04 Billion Opportunity Driven by Point-of-Care Diagnostics and Automation - GlobeNewswire Inc.
Grace Groner bought three $60 shares of Abbott Laboratories in 1935 and worked there 43 years; she left more than $7 million to benefit Lake Forest College students when she died at 100 - Parade Magazine
AG Fitch announces $384M false claims settlement with Abbott Laboratories - Picayune Item
Abbott Laboratories stock outperforms competitors on strong trading day - MarketWatch
Abbott Laboratories Stock (ABT) Moved Up by 3.08% on Oct 5: Facts Behind the Movement - TradingKey
Europe Point of Care Diagnostics Market Size and Forecast, 20212031 | Market to Reach US$21.4 Billion by 2031 as Rapid Testing and Molecular Innovation Drive 13.4% CAGR - GlobeNewswire Inc.
The Zacks Analyst Blog Highlights Abbott, Corcept, Precigen and Bausch Health Companies - Yahoo Finance
Abbott Laboratories (ABT) Launches SimpleScreen CRC As Fair Value Debate Heats Up - Simply Wall Street
How to Create a Million-Dollar Stock Portfolio - Zacks Investment Research
At $98.83 each, Abbott (ABT) director John G. Stratton acquires 397 share-linked units. - Stock Titan
DXCM Report Highlights CGM Growth Opportunity in Type 2 Diabetes Care - Zacks Investment Research
Here Are Friday’s Top Wall Street Analyst Research Calls: Abbott Laboratories, Airbnb, Cerebras Systems, Coinbase Global, Edison International, Northrop Grumman, Pershing Square, Robinhood Markets, and More - Yahoo Finance
Here Are Friday’s Top Wall Street Analyst Research Calls: Abbott Laboratories, Airbnb, Cerebras Systems, Coinbase Global, Edison International, Northrop Grumman, Pershing Square, Robinhood Markets, and More - 24/7 Wall St.
4 Low-Beta Healthcare Stocks to Buy Amid Fears of Another Rate Hike - Zacks Investment Research
Rothschild & Co Redburn Upgrades Abbott Laboratories to Buy From Neutral, Adjusts PT to $127 From $119 - Yahoo Finance
Abbott Laboratories vs. Intuitive Surgical: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Global Liver Cancer Diagnostics Market to Observe Impressive Growth at a CAGR of ~9% by 2034 | DelveInsight - GlobeNewswire Inc.
Abbott Laboratories’ Quarterly Earnings Preview: What You Need to Know - Barchart.com
Abbott (ABT) Sees a More Significant Dip Than Broader Market: Some Facts to Know - Zacks Investment Research
Abbott Laboratories stock trades at EUR 88.71 versus EUR 88.77, minus 0.07 percent - ad-hoc-news.de
Form 4 Abbott Laboratories For: 29 September By Investing.com - Investing.com UK
Abbott lawsuit alleges spinal cord stimulators can fail, worsen nerve damage - Top Class Actions
Global Therapeutic Drug Monitoring Consumables Market Forecast, 2026-2032AI-Enabled Automation and Integrated Lab Workflows Drive 8.22% CAGR, Lifting the Market to USD 586.85 Million by 2032 - GlobeNewswire Inc.
3 Dividend Stocks To Watch As High Rates Test Defensive Shares - simplywall.st
At $103.99 a share, an Abbott Laboratories (ABT) director delivered or withheld shares for exercise costs or taxes. - Stock Titan
How Lingo Partnership Will Impact Abbott Stock (ABT) - simplywall.st
Abbott Laboratories (ABT) is Facing Segment Competition and Sluggish Nutrition Recovery - Yahoo Finance
Mexico Cardiac Rhythm Management Devices Market Outlook to 2036 Provides Revenue, Volume, Pricing and Competitive Insig - GlobeNewswire Inc.
Abbott Laboratories: A Strong Business At A Fair Price (NYSE:ABT) - Seeking Alpha
Sinocare Asks Court To Rule Device Won't Infringe Abbott IP - Law360
Here's Why You Should Hold Stryker Stock in Your Portfolio for Now - Zacks Investment Research
What Makes Abbott Laboratories (ABT) an Attractive Opportunity? - Yahoo Finance
Abbott and Berry Street team up on personalized nutrition tracking - marketscreener.com
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
A 15% discount on Abbott's four-week glucose-monitor plans will go to Berry Street users. - Stock Titan
Finanzdaten der Abbott Laboratories-Aktie (ABT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Abbott Laboratories-Aktie (ABT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| John A. McCoy, Jr. | Officer |
Sep 02 '26 |
Proposed Sale |
109.52 |
27 |
2,957 |
0 |
| Robert B. Ford | Officer |
Aug 25 '26 |
Proposed Sale |
115.85 |
398,832 |
46,204,386 |
0 |
| Ford Robert B | CHAIRMAN AND CEO |
Aug 25 '26 |
Sale |
115.85 |
398,832 |
46,204,798 |
306,461 |
| Ford Robert B | CHAIRMAN AND CEO |
Aug 25 '26 |
Option Exercise |
54.02 |
398,832 |
21,545,946 |
705,293 |
| Morrone Louis H. | EXECUTIVE VICE PRESIDENT |
Aug 11 '26 |
Sale |
109.83 |
5,850 |
642,506 |
70,724 |
| Louis H. Morrone | Officer |
Aug 11 '26 |
Proposed Sale |
109.83 |
5,850 |
642,506 |
0 |
| Robert J. Alpern | Retired Director |
May 15 '26 |
Proposed Sale |
85.25 |
7,587 |
646,791 |
0 |
| Stratton John G | Director |
May 07 '26 |
Buy |
86.82 |
2,000 |
173,640 |
23,319 |
| STARKS DANIEL J | Director |
Apr 27 '26 |
Buy |
92.65 |
10,000 |
926,537 |
6,751,103 |
| Robert J. Alpern | Retired Director |
Apr 27 '26 |
Proposed Sale |
92.55 |
29,211 |
2,703,457 |
0 |
0.83%
0.36%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):